SCHEMBL1640583

SCHEMBL1640583

O=C(Nc1cccc(-c2ncoc2-c2ccnc(Nc3cccc(F)c3)n2)c1)c1c(F)cccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKMYT1 Q99640 1/20 0.54
IGF1R P08069 8/20 0.51
EGFR P00533 6/20 0.51
ERBB2 P04626 6/20 0.51
ABL1 P00519 5/20 0.50
BCR P11274 5/20 0.50
SLC2A1 P11166 3/20 0.50
PDGFRB P09619 3/20 0.50
PDGFRA P16234 3/20 0.50
BRAF P15056 2/20 0.49
SRC P12931 4/20 0.48
AURKA O14965 2/20 0.48
KDR P35968 2/20 0.48
AURKB Q96GD4 2/20 0.48
PRKD3 O94806 2/20 0.48
MAP4K4 O95819 1/20 0.48
CHEK2 O96017 1/20 0.48
NTRK1 P04629 1/20 0.48
INSR P06213 1/20 0.48
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431886 0.91 ABL1 (0.48) PKMYT1IGF1REGFRERBB2ABL1
SCHEMBL12726561 0.82 BRAF (0.54) PKMYT1IGF1REGFRERBB2ABL1
SCHEMBL1640589 0.81 CAMK2D (0.54) IGF1REGFRABL1BCRSRC
SCHEMBL12726212 0.81 BRAF (0.58) PKMYT1IGF1REGFRERBB2ABL1
SCHEMBL1642068 0.81 CDK4 (0.60) PKMYT1IGF1REGFRERBB2ABL1
SCHEMBL1641103 0.79 ABL1 (0.57) EGFRERBB2ABL1BCRSLC2A1
SCHEMBL3442268 0.78 SLC2A1 (0.76) PKMYT1IGF1REGFRERBB2SLC2A1
SCHEMBL3441774 0.78 PKMYT1 (0.65) PKMYT1IGF1REGFRERBB2ABL1
SCHEMBL13105497 0.77 PKMYT1 (0.63) PKMYT1IGF1REGFRERBB2SLC2A1
SCHEMBL3443667 0.77 SLC2A1 (0.71) PKMYT1IGF1REGFRERBB2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 PKMYT1 485/4885IGF1R 396/4885EGFR 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.